Inve US ▾
ININO

Inovio (INO) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 12, 2026

Source: earnings call transcript

Executive summary

Inovio Q2 FY26 — INO-3107 BLA Progress and Launch Preparations

Inovio is nearing a critical juncture with its lead candidate, INO-3107, for RRP, as the BLA review progresses towards an October PDUFA date. The company has strengthened its financial position to support a potential launch, while also advancing its broader pipeline through strategic partnerships. Management remains focused on addressing the significant unmet need in RRP with a differentiated product profile, despite the FDA's ongoing review of accelerated approval eligibility.

Highlights

5

  • INO-3107 BLA review advanced with late cycle meeting and pre-licensure inspections completed, on track for October 30, 2026 PDUFA date.

  • Equity offering raised $18.3 million in net proceeds, extending cash runway into late Q1 2027 and through potential INO-3107 launch.

  • ApolloBio, partner for VGX-3100, announced positive top-line Phase 3 results for cervical dysplasia, meeting primary efficacy endpoint.

  • Operating expenses decreased by 19% to $18.6 million in Q2 2026 and 16% in H1 2026, reflecting strategic resource management.

  • Net loss significantly reduced to $6 million ($0.07 per share) in Q2 2026 from $23.5 million ($0.61 per share) in Q2 2025.

Concerns

2

  • FDA did not discuss preliminary conclusion regarding accelerated approval eligibility for INO-3107 during the informal clinical meeting.

  • FDA's feedback on the confirmatory trial design for INO-3107 is still pending.

Guidance & targets

CategoryTargetConfidence
INO-3107 BLA PDUFA Target Date
October 30, 2026
high materiality
High
Cash Runway
Into late first quarter 2027
high materiality
High
Operational Net Cash Burn
Approximately $18 million
medium materiality
High
Orphan Drug Market Exclusivity
7 years
high materiality
High

Deals & partnerships

Syneos Health Contract sales organization to support U.S. commercialization of INO-3107.

Syneos Health has deep experience in rare disease launches and will serve as Inovio's CSO.

ApolloBio Partner for VGX-3100 in Greater China.

ApolloBio recently announced positive top-line Phase 3 results for VGX-3100 for cervical dysplasia and plans to seek regulatory approval in China.

Risks & headwinds

FDA not discussing accelerated approval eligibility During July 2026 informal clinical meeting

Not quantified

Mitigation:Management believes INO-3107 meets criteria for accelerated approval based on efficacy, tolerability, and differentiated MOA, and continues to engage with FDA.

Pending FDA feedback on confirmatory trial design Ongoing

Not quantified

Mitigation:Management expects comments to be forthcoming and does not believe it will impact approvability or PDUFA date.

Competition from existing treatments Current

Early uptake of [Papzimios] with approximately 200 patients treated, representing low single-digit penetration.

Mitigation:INO-3107 is positioned with competitive advantages, including not requiring additional surgery during dosing, differentiated MOA, and no ultra-cold chain handling.

What to watch in Q3 FY26

INO-3107 BLA Decision

October 30, 2026
Current On track for PDUFA date
Target FDA approval or other regulatory decision

Why it matters

This is the primary catalyst for INO-3107, determining its market entry and the company's future trajectory.

We are on track for the October 30 target PDUFA date.

Find out whether INO delivers this. Inve re-checks your case every morning.

Q&A highlights

Were any new efficacy, safety, or CMC-related questions raised by the FDA during the informal clinical meeting?

Mike Sumner stated that the FDA did not raise new questions on efficacy, safety, or CMC. They had previously received all data. The FDA did not comment on accelerated approval eligibility, as the file is under active review.

“They certainly have not disagreed with our positioning in terms of how we've presented our efficacy and safety data. But unfortunately, as you heard me say, they weren't in a position to comment on the eligibility question as the file is under active review.”

asked by [ Lien Chan ] from Jefferies · answered by Mike Sumner

2 min read 5 chapters

Detailed narrative

INO-3107 Regulatory Progress

The FDA's review of the BLA for INO-3107 is on track for an October 30, 2026 PDUFA date. Key milestones completed include the late cycle review meeting and all scheduled pre-licensure inspections (clinical, drug manufacturing, in-house drug testing, and delivery device facility), with only one reported observation that has been addressed. An informal clinical meeting was held in July where Inovio presented the totality of data supporting INO-3107's safety and efficacy, though the FDA did not comment on accelerated approval eligibility.

Commercial Launch Preparations

Inovio is actively building its critical launch infrastructure for INO-3107, leveraging experienced field teams. Syneos Health has been engaged as the contract sales organization for U.S. commercialization, and targeted marketing efforts are planned with an agency of record and a hub partner for patient support. These preparations aim to establish payer and hospital access, drive healthcare provider and patient preference, and educate the market about INO-3107's potential.

Differentiated Product Profile of INO-3107

INO-3107 is positioned as a potential new standard of care for RRP due to its differentiated profile. It treats RRP without requiring additional scoping and surgeries during the dosing window, unlike existing treatments where 83% of participants required at least one MRD surgery. The product also avoids potential impacts from immunosuppressive papilloma microenvironments or pre-existing neutralizing antibodies and does not require specialized ultra-cold chain handling, offering greater flexibility in care settings.

Pipeline Advancements through Partnerships

Inovio continues to advance its broader pipeline through strategic collaborations. ApolloBio, its partner for VGX-3100 in Greater China, announced positive top-line Phase 3 results for cervical dysplasia, meeting the primary efficacy endpoint and demonstrating a favorable safety profile. ApolloBio plans to seek regulatory approval in China. Additionally, Inovio presented promising preclinical data on its next-generation DNA-encoded protein (D-Prop) technology for hemophilia A and is exploring partnerships to advance D-Prop candidates for rare diseases like Fabry disease and hypophosphatasia.

Financial Position and Cash Runway

The company strengthened its balance sheet with a July 2026 equity offering, generating approximately $18.3 million in net proceeds. This extends the estimated cash runway into late first quarter 2027, covering a potential launch of INO-3107. Operating expenses decreased by 19% year-over-year to $18.6 million in Q2 2026 and by 16% for the first six months of 2026, reflecting strategic resource management. The net loss significantly improved to $6 million ($0.07 per share) in Q2 2026, compared to $23.5 million ($0.61 per share) in Q2 2025, partly due to a non-cash gain on warrant liabilities.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.